Key Market Indicator:
F&G: 23
25.279,00 NASDAQ · 47.521,00 DOW · 6.798,75 S&P · 4.239,07 Gold · 63,03 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
© ACCESSWIRE
26.02.2025
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec Announces Change in Management Board
News Preview
Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 HAMBURG, GERMANY / ACCESS Newswire / February 26, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Chief Financial O...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2025
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
News Preview
  Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy Funding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis   Hamburg, Germany, 22 Janu......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2025
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec erhält Fördermittel von der koreanischen Regierung zur Entwicklung neuartiger Antikörper-basierter Behandlungen für Lungenerkrankungen
News Preview
  Yonsei University, Zymedi und Evotec erhalten 4,5 Mio. USD von dem Korea Institute of Advanced Technology im Rahmen des koreanischen Ministeriums für Handel, Industrie und Energie. Die Finanzierung unterstützt eine neuartige Zusammenarbeit zur Entwicklung von First-in-Class-Therapeutika zur Behandlung von Asthma und idiopathischer Lunge......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar

USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
22.01.2025
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases
News Preview
Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22,...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
11.12.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk
News Preview
  Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding, adding Boston Children’s Hospital, Boston University, Johns Hopkins University, Jos......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE kündigt erste Projekte für den LAB eN² Accelerator mit Novo Nordisk an
News Preview
  Novo Nordisk und Evotec wählen drei Projekte von der Boston University, der Harvard University in Zusammenarbeit mit Mass General Brigham und dem Joslin Diabetes Center aus, die im Rahmen von LAB eN² entwickelt werden und sich auf kardiometabolische Erkrankungen konzentrieren LAB eN² erweitert sich und fügt das Boston Children’s Hospita......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
News Preview
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec gibt Veränderung im Vorstand bekannt
News Preview
Dr. Craig Johnstone tritt mit Wirkung zum 31. Dezember 2024 als Chief Operating Officer zurück Verantwortlichkeiten werden intern verteilt Hamburg, 29 November 2024: Die Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute bekannt, dass ihr Chief Operating Officer, Dr. Craig Johnstone, Evotec mit Wir......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec announces change in Management Board
News Preview
Dr Craig Johnstone steps down as Chief Operating Officer effective 31 December 2024 Distribution of responsibilities internally Hamburg, Germany, 29 November 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave th......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec Announces Change in Management Board
News Preview
Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Kommentar zum Rückzug eines unverbindlichen Angebots
News Preview
Ad hoc: Kommentar zum Rückzug eines unverbindlichen Angebots Hamburg – Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) Die Evotec SE hat die Erklärung der Halozyme Therapeutics Inc. vom 22. November 2024 zur Kenntnis genommen, wonach diese ihr unverbindliches Angebot zur Üb......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Comment on withdrawn non-binding offer
News Preview
Ad hoc: Comment on withdrawn non-binding offer Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Ev......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
22.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Comment on Withdrawn Non-Binding Offer
News Preview
HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO)Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ:EVO...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Comment on media report
News Preview
Ad hoc: Comment on media report Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) With respect to a media report, Evotec SE (“Company”) declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology ......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Kommentar zu Medienbericht
News Preview
Ad hoc: Kommentar zu Medienbericht Hamburg – Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) Die Evotec SE ("Gesellschaft") stellt mit Blick auf einen Medienbericht fest, dass sie ohne vorherige Kontaktaufnahme vom börsennotierten US-Biotechnologieunternehmen Halozyme Thera......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Comment on Media Report
News Preview
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotec...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Strategic Progress and Successful Expansion Amid Challenging Market Conditions
News Preview
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships  Successful extensions & expansions with BMS and Novo Nordisk; new collaboration......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Strategische Fortschritte und erfolgreiche Expansion in einem schwierigen Marktumfeld
News Preview
Prognose für 2024 bestätigt: Umsatzerlöse und bereinigtes EBITDA für das Gesamtjahr 2024 liegen im Plan, trotz herausfordernder Marktbedingungen Robustes Wachstum von Just – Evotec Biologics durch den Start weiterer Projekte zusammen mit Sandoz sowie Fortschritte bei Forschungspartnerschaften Erfolgreiche Erweiterungen & Expansion mit BMS und......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions
News Preview
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with...
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
News Preview
  Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners Transaction aligns with Evotec’s strategic optimization efforts, concentrating resources on key growth drivers New ownership committed to maintaining and growing the business   Hamburg, 05 November 2024: Evotec SE (Frankfur......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec gibt Verkauf von API-Produktionsanlage an Monacum Partners bekannt
News Preview
  Evotec veräußert auf API Herstellung fokussierten CDMO-Betrieb in Halle (Westf.) (Evotec DS) an Monacum Partners Transaktion ist Teil von Evotecs strategischer Optimierung, die eigenen Ressourcen auf Kernwachstumstreiber zu konzentrieren Neuer Eigentümer verpflichtet sich zum Erhalt und Ausbau des Geschäfts   Hamburg, 05 Nov......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.11.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
News Preview
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum PartnersTransaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth driversNew ownership committed to maintaining and growing the business HAMBURG, GERMANY / ACCESSWIRE / November 5, 2024 / Evotec SE (Frankfurt St...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE to announce results for the first nine months 2024 on 06 November 2024
News Preview
Hamburg, Germany, 30 October 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing ......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Bekanntgabe der Ergebnisse für die ersten neun Monate 2024 am 06. November 2024
News Preview
Hamburg, 30. Oktober 2024: Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) veröffentlicht am Mittwoch, 06. November 2024, ihren Bericht für die ersten neun Monate 2024. In einer Telefonkonferenz in englischer Sprache werden die Ergebnisse der ersten neun Monate präsentiert und erläutert. Außerdem wird......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.10.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
News Preview
HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.10.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec und Bristol Myers Squibb erweitern Proteomics-Partnerschaft
News Preview
  Wichtige wissenschaftliche Erfolge treiben den Ausbau der Pipeline von Molecular Glue Degraders in Bereichen außerhalb der Onkologie voran Evotec erhält eine Zahlung von 50 Mio. US$ von Bristol Myers Squibb; potenzielle programmbezogene Meilensteinzahlungen tragen zum Wert der Vereinbarung bei   Hamburg, 23 Oktober 2024: Evotec ......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.10.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec and Bristol Myers Squibb expand proteomics partnership
News Preview
  Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value   Hamburg, Germany, 23 October 2024: Evotec SE (Frankfurt Stock Exchange: EV......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.10.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec and Bristol Myers Squibb Expand Proteomics Partnership
News Preview
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncologyEvotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
News Preview
  Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies   Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a techn......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec und Novo Nordisk gehen Technologiepartnerschaft für Zelltherapien der nächsten Generation ein
News Preview
  Novo Nordisk stellt finanzielle Mittel für die Technologieentwicklung bei Evotec zur Verfügung, um die klinische und kommerzielle Herstellung von stammzellbasierten Therapien zu unterstützen   Hamburg, 26. September 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute bekannt, da......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
News Preview
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technolog...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Just – Evotec Biologics eröffnet hochmoderne Biologika-Anlage - J.POD® Toulouse, France (EU)
News Preview
  J.POD® Toulouse, France (EU) bringt disruptive, skalierbare, kontinuierliche Biologika-Herstellungstechnologie in die Region Just – Evotec Biologics J.POD®-Technologie bietet einen Paradigmenwechsel in der Bioproduktion mit kosteneffizienten und flexiblen Lösungen für die klinische und kommerzielle Versorgung   Hamburg und Toulo......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
News Preview
  J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions   Hamburg, Germany, and Toulouse, France, 20 Septemb......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
News Preview
  J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions   Hamburg, Germany, and Toulouse, France, 20 Septemb......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Just – Evotec Biologics eröffnet hochmoderne Biologika-Anlage - J.POD® Toulouse, France (EU)
News Preview
  J.POD® Toulouse, France (EU) bringt disruptive, skalierbare, kontinuierliche Biologika-Herstellungstechnologie in die Region Just – Evotec Biologics J.POD®-Technologie bietet einen Paradigmenwechsel in der Bioproduktion mit kosteneffizienten und flexiblen Lösungen für die klinische und kommerzielle Versorgung   Hamburg und Toulo......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)
News Preview
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the regionJust - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutionsHAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 2...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec gibt Veränderung im Vorstand bekannt
News Preview
  Dr. Matthias Evers tritt mit Wirkung zum 01. Oktober 2024 als Chief Business Officer zurück Verantwortlichkeiten werden auf andere Vorstandsressorts verteilt   Hamburg, 03. September 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute bekannt, dass ihr Chief Business Officer......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.09.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec announces change in Management Board
News Preview
  Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions   Hamburg, Germany, 03 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Business Officer, ......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Herausforderndes Jahr; Neuausrichtung für nachhaltiges profitables Wachstum aufbauend auf Kernkompetenzen gewinnt an Dynamik
News Preview
  Weicher Markt für Shared R&D Dienstleistungen; Umsatz geht im ersten Halbjahr 2024 im Vergleich zum Vorjahr um 7 % zurück. Anhaltendes Wachstum des Auftragsbestands im Bereich Discovery – höherer Anteil integrierter langfristiger Verträge wird Umsatzbeitrag über 2024 hinaus verbessern Starker Fortschritt von Just – Evotec Biologics ......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths
News Preview
  Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery – higher share of integrated long-term deals will improve revenue contribution beyond 2024 Strong progress of Just – Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity r......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
News Preview
  Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec   Hamburg, Germany, 13 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced further strong progr......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec verkündet starke Fortschritte in strategischer Partnerschaft mit Bristol Myers Squibb im Bereich Protein Degradation
News Preview
  Wichtige wissenschaftliche Erfolge treiben die Erweiterung der Pipeline von Molecular Glue Degraders voran Leistungs- und programmabhängige Zahlungen an Evotec in Höhe von insgesamt 75 Mio. US$   Hamburg, 13. August 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute weitere......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
News Preview
  Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research   Hamburg, Germany, 08 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership wit......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft mit Bristol Myers Squibb
News Preview
  Wichtiger wissenschaftlicher Fortschritt bringt die gemeinsame Neurologie - Pipeline voran und löst eine Zahlung von 25 Mio. US$ an Evotec aus, um die weitere Forschung voranzutreiben   Hamburg, 08. August 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute einen Fortschritt in ......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE berichtet Ergebnisse für das erste Halbjahr 2024 am 14. August 2024
News Preview
Hamburg, 07. August 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) veröffentlicht am Mittwoch, 14. August 2024, die Ergebnisse für das erste Halbjahr 2024. In einer Telefonkonferenz in englischer Sprache werden die Ergebnisse und Schwerpunkte aus dem Berichtszeitraum näher erläutert. Außerdem wird ......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE reports first half-year 2024 results on 14 August 2024
News Preview
  Hamburg, Germany, 07 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The con......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec provides guidance update
News Preview
  Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just – Evotec Biologics with mid double-digit revenue growth versus strong comparable basis Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France Further strengthened sales order book i......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec gibt Prognose Update bekannt
News Preview
  Navigieren durch ein herausforderndes H1 2024: Unbefriedigende Umsatzdynamik im Bereich Shared R&D; Just – Evotec Biologics mit mittlerem zweistelligem Umsatzwachstum gegenüber starkem vergleichbarem Vorjahreszeitraum Bereinigtes EBITDA durch hohe Fixkostenbasis im Bereich Shared R&D und Aufbaukosten für J.POD Toulouse, Frankrei......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE veröffentlicht Prognose Update
News Preview
Ad hoc: Evotec SE veröffentlicht Prognose Update Hamburg– Evotec SE (Frankfurter Wertpapierbörse: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) gibt bekannt, dass das Unternehmen seine Prognose für das Geschäftsjahr 2024 angepasst hat. Das Unternehmen erwartet einen Konzernumsatz von 790 – 820 Mio. € (niedriges bis mittlere......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec SE provides guidance update
News Preview
Ad hoc: Evotec SE provides guidance update Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024. The Company expects Group revenues in the range of € 790 – 820 m (low to mid-single-digit percent......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec and Pfizer collaborate to advance drug discovery in France
News Preview
  Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases   Hamburg, Germany, 10 July 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and licens......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec und Pfizer arbeiten zusammen, um Wirkstoffforschung in Frankreich voranzubringen
News Preview
  Die mehrjährige Zusammenarbeit wird sich zunächst auf die frühe Forschung und Entdeckung in den Bereichen Stoffwechsel- und Infektionskrankheiten konzentrieren   Hamburg, 10. Juli 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute bekannt, dass das Unternehmen eine mehrjährige ......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.07.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
News Preview
  Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security   Hamburg, Germany, and Seattle, WA, USA, 8 July 2024: Evotec SE ......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.07.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Just – Evotec Biologics erweitert Tech-Partnerschaft für Biosimilars mit Sandoz
News Preview
  Just – Evotec Biologics erweitert Partnerschaft mit Sandoz für Entwicklung und kommerzielle Herstellung von Biosimilars Sandoz-Entwicklungspipeline wird potenziell um weitere Biosimilars erweitert Weitere Garantien für Sandoz langfristige Liefersicherheit für Biosimilars   Hamburg, Deutschland und Seattle, USA, 08. Juli 2024......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Just – Evotec Biologics vom US-amerikanischen Verteidigungsministerium für Manufacturing Optimization Program ausgewählt
News Preview
  Just – Evotec Biologics wird eine ultraschnelle, kosteneffiziente Plattformlösung für die Herstellung von Biotherapeutika für das Manufacturing Optimization Program des US-amerikanischen Verteidigungsministeriums liefern Die Produktionslösung umfasst die nahtlose Integration der beschleunigten Entwicklung von mAb-Wirkstoffen in das Manu......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
News Preview
  Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimization Program Manufacturing Optimization P......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.06.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
News Preview
  Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research   Hamburg, Germany, 12 June 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today th......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.06.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Evotec gibt Fortschritt in Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
News Preview
  Wichtiger wissenschaftlicher Fortschritt stärkt die gemeinsame Pipeline der strategischen Neurologie-Partnerschaft mit Bristol Myers Squibb und löst eine Zahlung von 20 Mio. US$ an Evotec aus, um die weitere Forschung voranzutreiben   Hamburg, 12. Juni 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE000566480......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.06.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Ergebnisse der Hauptversammlung 2024
News Preview
  Die meisten Tagesordnungspunkte mit großer Mehrheit beschlossen Hauptversammlung 2024 wählt Dr. Duncan McHale und Wesley Wheeler in den Aufsichtsrat; Dr. Elaine Sullivan und Dr. Mario Polywka scheiden aus dem Aufsichtsrat aus   Hamburg, 10. Juni 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; ......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.06.2024
ISIN: DE0005664809

Evotec SE
EVT

LISTED

XETR
Results of the Annual General Meeting 2024
News Preview
  Most agenda items adopted with great majority Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario Polywka   Hamburg, Germany, 10 June 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced......
Themefolio
Profiler
Peergroup

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2025 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.